BCAX Bicara Therapeutics Inc.

XNAS 10.46 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

BCAX $10.46 —
Key stats
$10.46
52-Week Range
$7.87 – $30.99
YTD
-36.12%
IV Rank (30D)
25.77
Straddle Price
$4.50
P/C Vol Ratio
0.30
Market Cap
$0.7B
Open
$10.35
Day Range
$10.11 – $10.60
Volume
48,571
Prev Close
$10.18
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.86%
Beta vs SPY1.37
Cost of Equity (CAPM)11.37% (VRP-adj)
WACC12.05%
Volatility Risk Premium-4.3pp (IV − HV30), ERP adj -25bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-39.5%
Book / Price67.8% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$17.63 (Market Anchor value)
SMA 20 / Bollinger Mid$13.30
Bollinger Width / SMA20126.3% (drives anchor stability)
Net Debt$-0.1B
Market Cap$1B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
55%
20-Day Fair Value
≈ by Dec 10, 2026
ACTIVE
$10.26
α +0.8% rank 97%
conviction
57%
40-Day Fair Value
≈ by Jan 8, 2027
ACTIVE
$10.55
α +3.7% rank 98%
conviction
88%
60-Day Fair Value
≈ by Feb 8, 2027
ACTIVE
$10.40
α +2.2% rank 98%
conviction
55%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 41.3× · 3 peers
Peer EV/EBITDA n/a 0% median 20.7× · 3 peers
Peer P/B $25.88 19% median 3.8× · 3 peers
Peer P/S n/a 0% median 4.0× · 3 peers
Market Anchor (SMA50) $17.63 81% stability 85% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-11-11 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.7B
Employees
103
List Date
2024-09-13
CIK
0002023658
Last Earnings
Nov 9 before open · +15.4% vs ±56.9% expected
Headquarters
Boston, MA
Homepage
https://www.bicara.com

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'24'25'26Avg
Jan---25.44%2.56%-11.44%
Feb--8.13%0.12%4.12%
Mar--2.60%13.08%7.84%
Apr--13.51%5.27%9.39%
May---37.12%0.37%-18.38%
Jun---6.16%43.99%18.91%
Jul--17.44%-7.03%5.21%
Aug--13.39%-10.18%1.61%
Sep8.80%32.69%-20.54%6.98%
Oct-3.07%-2.17%-49.84%-18.36%
Nov-13.41%16.15%28.37%*10.37%
Dec-12.94%-2.89%---7.92%
Total-20.50%8.02%-24.52%-12.33%
* Only 3 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $13.30
SMA 50: $17.63
SMA 200: $20.93
Current: $10.18
EMA 12: $10.79
EMA 26: $13.46
MACD: -2.6730 | Signal: -0.1382
BEARISH
ADX (14): 53.67
STRONG TREND
+DI: 12.60
−DI: 37.85

Momentum Oscillators

RSI (14): 33.76
NEUTRAL
Stoch %K: 16.38
Stoch %D: 10.89
Williams %R: -77.35

Volume & Volatility

BB Upper: $21.69
BB Lower: $4.90
NEUTRAL
OBV: -15,499,224
Vol SMA 20: 2,136,804
Vol ROC: 220.17%
ATR: $1.34
True Range: $0.88
HV 20: 231.7%
HV 30: 189.5%
HV 60: 137.5%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before BCAX’s Nov 9 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

Executive Summary Overall assessment: NEUTRAL with confidence level (6/10) Key drivers and primary risks: * Technical signals indicate a neutral market, but recent news headlines suggest potential for growth. * High IV premium indicates high volatility, which may lead to significant price movements. * Beta of 0.98 suggests moderate volatility relative to the market.

Technical Analysis Trend Direction: Short-term (1-4 weeks) - Neutral; Medium-term (1-3 months) - Uptrend; Long-term (3-12 months) - Bullish

Support/Resistance Levels: * SMA 20: $26.35 * SMA 50: $26.00 * SMA 200: $20.38 * Upper Bollinger Band: $29.24

Momentum Signals: * RSI (14): 44.97 - Neutral * MACD: -0.54 / Signal: -0.35 / Histogram: -0.19 - Bearish signal

Volume Analysis: * Volume SMA 20: 648922.11 * On-Balance Volume (OBV): 19609362.33 * Volume Rate of Change: 8.92% - Increasing volume suggests potential for continued price growth.

News & Sentiment Analysis Recent Headlines Summary: Positive news headlines, including the company's CEO selling shares and pricing a public offering, suggest potential growth.

Sentiment Assessment: POSITIVE

Catalyst Identification: * Earnings announcements * Product launches * Regulatory changes

Market Narrative: The recent positive news headlines may have led to increased investor interest, as indicated by the rising volume and OBV. This could continue to drive price growth in the short term.

Risk & Volatility Assessment Beta Interpretation: 0.98 (Moderate volatility relative to market)

Volatility Regime: Moderate

Options Market Signals: * IV Rank: 2.6% - Low * Current IV: 73.8% * Expected Move: $5.05 (32 DTE), 7-DTE: $1.93 * Volume Flow: 2 calls vs 0 puts * Open Interest: 2 calls vs 0 puts

Downside Protection: The company's beta of 0.98 suggests moderate volatility relative to the market. The recent positive news headlines may continue to drive price growth, but there is still a risk of price corrections.

Market Context & Positioning Sector Performance: BCAX has outperformed its sector in the short term.

Institutional Activity: * Volume patterns suggest institutional interest, which could continue to drive price growth.

Correlation Analysis: * Correlation coefficient: 0.21 * Interpretation: Moderate correlation with market

Relative Valuation: BCAX is relatively undervalued compared to its sector peers.

Key Levels & Action Items Critical Price Levels: * SMA 20: $26.35 * Upper Bollinger Band: $29.24

Breakout/Breakdown Levels: * SMA 50: $26.00 * SMA 200: $20.38

Time-Sensitive Catalysts: * Earnings announcements * Product launches * Regulatory changes

Risk Management: Stop-loss levels and position sizing considerations are crucial for managing risk.

Please note that the analysis provided is based on the data available, but there may be additional factors that have not been considered.

Generated
News
All BCAX news →
Earnings History
6 of 6 under expected move
Avg Expected Move
25.48%
Avg Actual Move
7.09%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2025-05-13 unknown 26.46% 5.06% 0.19x Within
2025-08-12 unknown 16.24% 8.21% 0.51x Within
2025-11-10 unknown 25.31% 5.74% 0.23x Within
2026-03-30 unknown 12.34% 4.46% 0.36x Within
2026-08-11 unknown 15.57% 3.66% 0.24x Within
2026-11-09 Pre-Market 56.94% 15.38% 0.27x Within

Earnings calendar: this week’s reports with expected vs actual moves →

BCAX Options Activity & IV Rank

BCAX IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 81.8%
7-DTE IV: —
Expected Move: $4.50
7-DTE Move: $4.50
Days to Exp: 37 (2026-12-18)

Options Flow · All expiries

Call Volume: 2,496
Put Volume: 747
P/C Volume: 0.299
BULLISH
Call OI: 5,907
Put OI: 3,344
P/C OI: 0.566
Total OI: 9,251

ATM Options Pricing

ATM Call: $2.50
ATM Put: $2.00
Call %: 23.9%
Put %: 19.1%

Chain Summary

Chain Volume: 3,243
Chain OI: 9,251
Last Updated: 11/11/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 69th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
69%
vs own history
GEX tilt
-0.67
OI-weighted, today
Vanna tilt
+0.99
δ-sensitivity to IV
Charm tilt
-0.99
δ-decay vs time
Vanna tilt +0.99: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.99: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 4 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Nov 10 · No data
30 DTE / 10d —
— pts EXTREME
as of Nov 10 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)25.8MediumNov 11

Embed BCAX IV rank

BCAX's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$4.50Nov 11
Beta Analysis

Risk Metrics

Beta: 1.2771
Alpha: -13.56%
Correlation: 0.2368
R-Squared: 5.6%
Stock Volatility: 73.7%
Market Volatility: 13.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own BCAX
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$7.8M
0.01%
#1768 of 3716+67.4%13F
Citadel Hedge fund
Ken Griffin
$6.3M
0.00%
#1914 of 6285-87.3%13F
Rockefeller Capital Management Family office
Rockefeller family
$8K
0.00%
#4079 of 4729-52.6%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

BCAX Institutional Ownership (13F)

Filings for 2026-06-30 · 49 already for 2026-09-30
Diluted shares outstanding: 59,588,710 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

167 filers69,951,105 shares$2.00B value117.39% of float
# Filer Shares Value % of Total % of Float Period
1 RA CAPITAL MANAGEMENT, L.P. 7,255,993 $215.43M 10.76% 12.18% 2026-06-30
2 T. Rowe Price Investment Management, Inc. 6,338,487 $188.19M 9.40% 10.64% 2026-06-30
3 Siren, L.L.C. 5,602,970 $166.35M 8.31% 9.40% 2026-06-30
4 Vestal Point Capital, LP 5,250,000 $155.87M 7.79% 8.81% 2026-06-30
5 Deep Track Capital, LP 4,100,000 $121.73M 6.08% 6.88% 2026-06-30
6 BlackRock, Inc. Custodian 3,848,090 $114.25M 5.71% 6.46% 2026-06-30
7 Jupiter Topco LLC 3,171,015 $93.96M 4.69% 5.32% 2026-06-30
8 TPG GP A, LLC 3,010,425 $89.38M 4.47% 5.05% 2026-06-30
9 Vanguard Capital Management LLC 2,216,639 $65.81M 3.29% 3.72% 2026-06-30
10 State Street Corp 2,048,920 $60.83M 3.04% 3.44% 2026-06-30
11 Franklin Resources, Inc. Custodian 1,951,892 $57.95M 2.90% 3.28% 2026-06-30
12 T. Rowe Price Associates, Inc. 1,904,248 $56.54M 2.82% 3.20% 2026-06-30
13 FMR LLC Custodian 1,893,070 $56.21M 2.81% 3.18% 2026-06-30
14 Red Tree Management, LLC 2,920,509 $54.35M 2.72% 4.90% 2026-09-30
15 Omega Fund Management, LLC 1,822,150 $54.10M 2.70% 3.06% 2026-06-30
16 JPMorgan Chase & Co Custodian 1,015,965 $29.81M 1.49% 1.71% 2026-06-30
17 Jones Hill Capital LP 892,621 $26.50M 1.32% 1.50% 2026-06-30
18 Geode Capital Management, LLC Custodian 1,178,536 $21.94M 1.10% 1.98% 2026-09-30
19 ACORN CAPITAL ADVISORS, LLC 643,381 $19.10M 0.95% 1.08% 2026-06-30
20 Aisling Capital Management LP 568,919 $16.89M 0.84% 0.95% 2026-06-30
21 Palo Alto Investors LP 550,408 $16.34M 0.82% 0.92% 2026-06-30
22 Rock Springs Capital Management LP 535,286 $15.89M 0.79% 0.90% 2026-06-30
23 Goldman Sachs Group Inc Custodian 520,567 $15.46M 0.77% 0.87% 2026-06-30
24 D. E. Shaw & Co., Inc. Custodian 498,193 $14.79M 0.74% 0.84% 2026-06-30
25 Vanguard Portfolio Management LLC 418,912 $12.44M 0.62% 0.70% 2026-06-30
5 filers$2.08M notional
# Filer Notional Value % of Total Period
1 Caption Management, LLC $890.70K 42.76% 2026-06-30
2 NOMURA HOLDINGS INC $623.49K 29.93% 2026-06-30
3 Susquehanna International Group, LLP Custodian $388.94K 18.67% 2026-06-30
4 GROUP ONE TRADING LLC Custodian $178.14K 8.55% 2026-06-30
5 Simplex Trading, LLC Custodian $1.86K 0.09% 2026-09-30
7 filers$6.24M notional
# Filer Notional Value % of Total Period
1 Citadel Advisors LLC Custodian $2.73M 43.68% 2026-06-30
2 Caption Management, LLC $890.70K 14.28% 2026-06-30
3 Susquehanna International Group, LLP Custodian $843.20K 13.51% 2026-06-30
4 NOMURA HOLDINGS INC $623.49K 9.99% 2026-06-30
5 Jane Street Group, LLC Custodian $528.48K 8.47% 2026-06-30
6 GROUP ONE TRADING LLC Custodian $460.19K 7.38% 2026-06-30
7 Simplex Trading, LLC Custodian $167.49K 2.68% 2026-09-30

BCAX Insider Trading (Form 4)

Latest: 2026-09-10
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-10 Ryan Cohlhepp President, COO & Interim CEO Mixed
Exer +17,500 · Sell −17,500
 — $13.34 -$334.4K EDGAR
2026-08-14 Jennifer Larson Chief Financial Officer Grant (A) +285,000 opt — EDGAR
2026-08-12 Claire Mazumdar Chief Executive Officer Mixed
Exer +10,000 · Sell −10,000
 — $15.88 -$241.9K EDGAR
2026-08-12 Ivan Hyep Chief Financial Officer Mixed
Exer +12,500 · Sell −12,500
 — $15.88 -$302.2K EDGAR
2026-08-12 Ryan Cohlhepp President and COO Mixed
Sell −18,750 · Exer +18,750
 — $15.88 -$453.5K EDGAR
2026-07-29 Jeremy Bender Director Grant (A) +38,950 opt — EDGAR
2026-07-29 Christy J. Oliger Director Grant (A) +38,950 opt — EDGAR
2026-07-14 Claire Mazumdar Chief Executive Officer Mixed
Exer +10,000 · Sell −10,000
 — $16.10 -$246.3K EDGAR
2026-07-10 Ryan Cohlhepp President and COO Mixed
Sell −28,750 · Exer +18,750
 −10,000 $19.04 -$762.1K EDGAR
2026-07-10 Ivan Hyep Chief Financial Officer Mixed
Sell −28,000 · Exer +12,500
 −15,500 $21.11 -$760.3K EDGAR
2026-06-10 Kiran Mazumdar-Shaw Director Grant (A) +19,475 opt — EDGAR
2026-06-10 Christopher Bowden Director Grant (A) +19,475 opt — EDGAR
2026-06-10 RA CAPITAL MANAGEMENT, L.P. Director Grant (A) +19,475 opt — EDGAR
2026-06-10 Kate Haviland Director Grant (A) +19,475 opt — EDGAR
2026-06-10 Michael Powell Director Grant (A) +19,475 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

BCAX Insider Holdings

7 insiders · @ $10.18
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 RA Capital Healthcare Fund LP Director 4,603,418 $46.86M $4.80M 2 2026-03-02
2 Peter Kolchinsky Director 4,303,418 $43.81M $32.99M 2 2025-06-10
3 Claire Mazumdar Chief Executive Officer 362,152 $3.69M -$4.06M 12 2026-08-12
4 Kiran Mazumdar-Shaw Director 324,552 $3.30M $0 3 2026-06-10
5 Ryan Cohlhepp President, COO & Interim CEO 181,641 $1.85M -$4.60M 16 2026-09-10
6 Ivan Hyep Chief Financial Officer 129,855 $1.32M -$3.24M 12 2026-08-12
7 David Raben Chief Medical Officer 55,286 $562.8K -$1.15M 7 2026-04-28
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

BCAX Board & Officers

As of SEC filings through Sep 10, 2026

Directors 17

Officers 6

10% owners 5

Changes in the last 10 years (58)
Aug 12, 2026Jennifer Larson became Chief Financial Officer
Aug 12, 2026Ivan Hyep reported in an SEC filing no longer being Chief Financial Officer
Jul 28, 2026Jeremy Bender became a director
Jul 28, 2026Christy J. Oliger became a director
May 8, 2026William Schelman became Chief Medical Officer
Oct 8, 2025Ryan Cohlhepp first listed as a director in an SEC filing
Sep 18, 2024Tpg Gp A, LLC reported in an SEC filing no longer being a 10% owner
Sep 18, 2024Jon Winkelried reported in an SEC filing no longer being a 10% owner
Sep 18, 2024James G Coulter reported in an SEC filing no longer being a 10% owner
Sep 18, 2024Fmr LLC reported in an SEC filing no longer being a 10% owner
Sep 18, 2024FIL Ltd reported in an SEC filing no longer being a 10% owner
Sep 18, 2024David Bonderman reported in an SEC filing no longer being a 10% owner
Sep 17, 2024James E Flynn reported in an SEC filing no longer being a 10% owner
Sep 17, 2024Deerfield Private Design Fund V, L.P. reported in an SEC filing no longer being a director
Sep 17, 2024Deerfield Partners, L.p. reported in an SEC filing no longer being a 10% owner
Sep 17, 2024Deerfield Mgmt V, L.P. reported in an SEC filing no longer being a 10% owner
Sep 17, 2024Deerfield Mgmt L.P. reported in an SEC filing no longer being a 10% owner
Sep 17, 2024Deerfield Management Company, L.p. (series C) reported in an SEC filing no longer being a 10% owner
Sep 16, 2024RA Capital Nexus Fund III, L.P. no longer listed as a 10% owner in SEC filings
Sep 16, 2024RA Capital Nexus Fund III, L.P. first listed as a director in an SEC filing
Not reported recently (2)
  • Biocon Pharma Inc. · Last reported as a 10% owner in an SEC filing dated Sep 16, 2024
  • Biocon Ltd · Last reported as a 10% owner in an SEC filing dated Sep 16, 2024
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

BCAX Proposed Insider Sales (Form 144)

Latest: 2026-10-21
Last 30d: 1 filing · $449K notice value  ·  Last 90d: 6 filings · $2.3M notice value · 4 unique filers · 83% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Cohlhepp Ryan (2, $918K) · Hyep Ivan (2, $631K) · DAVID RABEN (1, $449K) · Mazumdar Claire (1, $278K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-10-21 DAVID RABEN Officer 24,777 $449.0K 2026-10-21 Morgan Stanley Smith Barney LLC … — EDGAR
2026-09-08 Hyep Ivan Officer 12,500 $283.0K 2026-09-08 UBS Financial Services, Inc. 10b5-1 EDGAR
2026-09-08 Cohlhepp Ryan Officer, Director 17,500 $396.2K 2026-09-08 UBS Financial Services, Inc 10b5-1 EDGAR
2026-08-10 Hyep Ivan Officer 12,500 $347.9K 2026-08-10 UBS Financial Services, Inc. 10b5-1 EDGAR
2026-08-10 Cohlhepp Ryan Officer, Director 18,750 $521.8K 2026-08-10 UBS Financial Services, Inc 10b5-1 EDGAR
2026-08-10 Mazumdar Claire Officer, Director 10,000 $278.3K 2026-08-10 UBS Financial Services, Inc. 10b5-1 EDGAR
2026-07-10 Mazumdar Claire Officer, Director 10,000 $296.8K 2026-07-10 UBS Financial Services, Inc. 10b5-1 EDGAR
2026-07-08 Cohlhepp Ryan Officer, Director 28,750 $869.7K 2026-07-08 UBS Financial Services, Inc 10b5-1 EDGAR
2026-07-08 Hyep Ivan Officer 28,000 $847.0K 2026-07-08 UBS Financial Services, Inc. 10b5-1 EDGAR
2026-07-08 DAVID RABEN Officer 50,000 $1.43M 2026-07-08 Morgan Stanley Smith Barney LLC … — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-09
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-09 Earnings results EDGAR
2026-08-25 Material agreement EDGAR
2026-08-11 Earnings results EDGAR
2026-07-28 Director or officer change · Regulation FD disclosure EDGAR
2026-06-10 Shareholder vote results EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-09 0001628280-26-072169 EDGAR
2026-08-11 0001628280-26-055765 EDGAR
ETF Holders
55 ETFs hold BCAX
25 shown · $96.95M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $31.2M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.01% $11.4M $77.8B 2026-11-09
3 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.11% $11.2M $10.5B 2026-11-09
4 VXF Vanguard Extended Market ETF Vanguard 0.01% $9.1M — 2026-09-30
5 VTWO Vanguard Russell 2000 ETF Vanguard 0.03% $4.8M — 2026-09-30
6 SCHA Schwab U.S. Small-Cap ETF Nport 0.02% $4.7M — 2026-08-31
7 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.03% $3.6M $14.1B 2026-11-09
8 IBB iShares Biotechnology ETF iShares (BlackRock) 0.03% $3.3M $11.3B 2026-11-09
9 DFAS Dimensional US Small Cap ETF Dimensional 0.01% $2.6M — 2026-11-09
10 SBIO ALPS Medical Breakthroughs ETF Nport 0.78% $1.9M — 2026-08-31
11 VHT Vanguard Health Care ETF Vanguard 0.01% $1.6M — 2026-09-30
12 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.02% $1.6M $6.8B 2026-11-09
13 TMSL T. Rowe Price Small-Mid Cap ETF Nport 0.06% $1.6M — 2026-06-30
14 DFMC Dimensional US Micro Cap ETF Dimensional 0.02% $1.2M — 2026-11-09
15 CANC Tema Oncology ETF Nport 0.41% $866,977 — 2026-08-31
16 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.03% $847,402 $3.2B 2026-11-09
17 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $838,570 — 2026-11-09
18 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.05% $778,922 — 2026-09-30
19 OPTZ Optimize Strategy Index ETF Nport 0.25% $709,977 — 2026-06-30
20 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $676,175 $95.3B 2026-11-09
21 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $630,906 — 2026-11-09
22 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $567,688 — 2026-08-31
23 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.00% $562,074 $14.1B 2026-11-09
24 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.02% $434,359 — 2026-07-31
25 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.07% $416,455 — 2026-11-10
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-3.10
TTM Revenue
—
TTM Net Income
$-185.36M
TTM Op. Cash Flow
$-134.85M
Quarterly figures (8 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30—$-55.44M$-0.82$-44.21M
Q1 '262026-03-31—$-56.21M$-0.93$-37.51M
Q4 '252025-12-31—$-37.39M$-0.68$-23.89M
Q3 '252025-09-30—$-36.33M$-0.67$-29.25M
Q2 '252025-06-30—$-27.39M$-0.50$-25.59M
Q1 '252025-03-31—$-36.85M$-0.68$-28.11M
Q4 '242024-12-31—$-20.96M$7.22$-30.03M
Q3 '242024-09-30—$-17.48M$-1.60$-17.22M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.29
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-39.5%
ROA
-36.2%
Div Yield
0.00%
FCF Yield
-22.23%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$606.61M
as of 2026-11-10

BCAX vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.26T 46.5 +45.5% +32.6% 27
GILD Gilead Sciences Inc $210.0B — +6.5% +40.5% 43
RVMD Revolution Medicines, Inc. Common Stock $43.3B — — +144.3% 60
APGE Apogee Therapeutics, Inc. Common Stock $10.2B — — +78.2% —
CGON CG Oncology, Inc. Common stock $6.7B — +666.0% +73.8% 97
COGT Cogent Biosciences, Inc. Common Stock $5.8B — — −8.9% 73
IDYA IDEAYA Biosciences, Inc. Common Stock $3.1B — −83.0% −6.2% 74
IMNM Immunome, Inc. $2.3B — — −10.4% 61
BCAX Bicara Therapeutics Inc. Common Stock $660M — — −37.9% 40
Peer median $8.4B 46.5 +26.0% +36.5% 61

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
10.30M
SI % of Float
23.85%
Days to Cover
11.53
Short Vol Ratio
63.9%
Free Float
43.17M
Float %
65.2%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-08-14